US paus­es use of Eli Lil­ly Covid-19 mAb com­bo in six more states due to vari­ants from Brazil, In­dia

As the com­bined fre­quen­cy of the Covid-19 vari­ants first iden­ti­fied in Brazil and South Africa now ex­ceeds 10% in Ari­zona, Cal­i­for­nia, Flori­da, In­di­ana, Ore­gon and Wash­ing­ton, the US said Wednes­day that it’s halt­ing all ship­ments to those states of Eli Lil­ly’s mAb com­bo to treat Covid-19 pri­or to hos­pi­tal­iza­tions.

The FDA rec­om­mends that health care providers in those six states use Re­gen­eron’s mAb cock­tail as an al­ter­na­tive au­tho­rized mon­o­clon­al an­ti­body ther­a­py be­cause it’s more ef­fec­tive against the vari­ants than the Lil­ly treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.